NCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
18 trialsNCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
NCT04072952 2026-04-15
mBC
Arvinas Inc.
Phase 1/2 Completed
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT04553133 2026-04-13
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT04767594 2026-04-13
PERFORM
Pfizer
Active not recruiting
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05399329 2026-04-09
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
Pfizer
Completed
NCT06188520 2026-04-08
CYCAD-1
AstraZeneca
Phase 1/2 Recruiting
NCT06997029 2026-04-07
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT06065748 2026-04-06
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT06962969 2026-04-02
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
Pfizer
Completed
NCT04654208 2026-03-31
SIRI
Pfizer
Recruiting
NCT05039177 2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2 Completed
NCT07492641 2026-03-25
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
BeOne Medicines
Phase 3 Not yet recruiting
NCT07347600 2026-03-20
reaINAVO
Hoffmann-La Roche
Recruiting